These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8935644)

  • 1. Clinical manifestations of transdermal scopolamine addiction.
    Luetje CM; Wooten J
    Ear Nose Throat J; 1996 Apr; 75(4):210-4. PubMed ID: 8935644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus.
    Pyykkö I; Padoan S; Schalén L; Lyttkens L; Magnusson M; Henriksson NG
    Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans.
    Gowans J; Matheson A; Darlington CL; Smith PF
    J Vestib Res; 2000; 10(2):87-92. PubMed ID: 10939683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of transcutaneous scopolamine and depth on diver performance.
    Williams TH; Wilkinson AR; Davis FM; Frampton CM
    Undersea Biomed Res; 1988 Mar; 15(2):89-98. PubMed ID: 3363755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scopoderm: transdermal hyoscine for motion sickness.
    Drug Ther Bull; 1989 Nov; 27(23):91-2. PubMed ID: 2519317
    [No Abstract]   [Full Text] [Related]  

  • 12. Accidental mydriasis from scopolamine patches.
    Rosen NB
    J Am Optom Assoc; 1986 Jul; 57(7):541-2. PubMed ID: 3745760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD; Rapaport MH
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of drooling using transdermal scopolamine skin patches. A case report.
    Mato Montero A; Limeres Posse J; Tomás Carmona I; Fernández Feijoo J; Diz Dios P
    Med Oral Patol Oral Cir Bucal; 2008 Jan; 13(1):E27-30. PubMed ID: 18167476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery.
    Sah N; Ramesh V; Kaul B; Dalby P; Shestak K; Vallejo MC
    J Clin Anesth; 2009 Jun; 21(4):249-52. PubMed ID: 19502023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new antinauseant drug for the prevention of motion sickness.
    Graybiel A; Knepton J
    Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151
    [No Abstract]   [Full Text] [Related]  

  • 17. Visual side-effects from transdermal scopolamine (hyoscine).
    Firth AY; Walker K
    Dev Med Child Neurol; 2006 Feb; 48(2):137-8. PubMed ID: 16417670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN; Ezzo DC
    Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron.
    Jones S; Strobl R; Crosby D; Burkard JF; Maye J; Pellegrini JE
    AANA J; 2006 Apr; 74(2):127-32. PubMed ID: 16617916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.